Guizhen Z, Guanchang J, Liwen L, Huifen W, Zhigang R, Ranran S et al. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Front Endocrinol (Lausanne). 2022;13:918869.

Article  PubMed  PubMed Central  Google Scholar 

Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430–3446.

Article  PubMed  Google Scholar 

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;731 Suppl 1:4–13.

Article  Google Scholar 

Mohamed EA, Giama NH, Abdalla AO, Shaleh HM, Oseini AM, Ali HA et al. High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. World J Gastroenterol. 2022;28:5217–5229.

Article  PubMed  PubMed Central  Google Scholar 

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.

Article  PubMed  Google Scholar 

Sondergaard JN, Sommerauer C, Atanasoai I, Hinte LC, Geng K, Guiducci G et al. CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism. Gut. 2022;71:2081–2092.

Article  CAS  PubMed  Google Scholar 

Li S, Yao J, Xie M, Liu Y, Zheng M. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J Hematol Oncol. 2018;11:54.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42:629–652.

Article  PubMed  Google Scholar 

Finn RS. Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer. 2012;1:247–256.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Chen Y, Zhang J, Yang Y, Fleishman JS, Wang Y et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updat. 2024;72:101018.

Article  CAS  PubMed  Google Scholar 

Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev. 2024;321:211–227.

Article  CAS  PubMed  Google Scholar 

Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254–1261.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.

Article  CAS  PubMed  Google Scholar 

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel MS, Nemeria NS, Furey W, Jordan F. The pyruvate dehydrogenase complexes: structure-based function and regulation. J Biol Chem. 2014;289:16615–16623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kolobova E, Tuganova A, Boulatnikov I, Popov KM. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J. 2001;358:69–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golias T, Papandreou I, Sun R, Kumar B, Brown NV, Swanson BJ et al. Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci Rep. 2016;6:31146.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Yu M, Fei B, Fang X, Ma T, Wang D. miR-21-5p targets PDHA1 to regulate glycolysis and cancer progression in gastric cancer. Oncol Rep. 2018;40:2955–2963.

CAS  PubMed  Google Scholar 

Li Y, Li X, Li X, Zhong Y, Ji Y, Yu D et al. PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. Oncotarget. 2016;7:53837–53852.

Article  PubMed  PubMed Central  Google Scholar 

Zhong C, Long Z, Yang T, Wang S, Zhong W, Hu F et al. M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy. Int J Biol Sci. 2023;19:1543–1563.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen KY, Liu Z, Yi J, Hui YP, Song YN, Lu JH et al. PDHA1 alleviates myocardial ischemia-reperfusion injury by improving myocardial insulin resistance during cardiopulmonary bypass surgery in rats. Cardiovasc Drugs Ther. 2023;39:17–31.

Article  PubMed  Google Scholar 

Cobine PA, Brady DC. Cuproptosis: cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell. 2022;82:1786–1787.

Article  CAS  PubMed  Google Scholar 

Chen J, Li ZY, Zheng G, Cao L, Guo YM, Lian Q et al. RNF4 mediated degradation of PDHA1 promotes colorectal cancer metabolism and metastasis. NPJ Precis Oncol. 2024;8:258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Geng R, Huang Y, Zhang J, Cheng H, Zhou C et al. AP2alpha negatively regulates PDHA1 in cervical cancer cells to promote aggressive features and aerobic glycolysis in vitro and in vivo. J Gynecol Oncol. 2023;34:e59.

Article  PubMed  PubMed Central  Google Scholar 

Olou AA, Ambrose J, Jack JL, Walsh M, Ruckert MT, Eades AE et al. SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. J Cell Commun Signal. 2023;17:575–590.

Article  CAS  PubMed  Google Scholar 

Liu X, Luo B, Wu X, Tang Z. Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:189013.

Article  CAS  PubMed  Google Scholar 

Yang L, Yang P, Lip GYH, Ren J. Copper homeostasis and cuproptosis in cardiovascular disease therapeutics. Trends Pharmacol Sci. 2023;44:573–585.

Article  CAS  PubMed  Google Scholar 

Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology. 2024;79:926–940.

PubMed  Google Scholar 

Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwalder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease—novel insights into cellular communication circuits. J Hepatol. 2022;77:1136–1160.

Article  CAS  PubMed  Google Scholar 

Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961.

Article  CAS  PubMed